New radiation boost shows promise for elderly glioblastoma patients

NCT ID NCT05565521

Ongoing Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a higher radiation dose given over just 3 weeks for patients 65 and older with glioblastoma or grade 4 astrocytoma. Using a special MRI-guided machine (MR-Linac), doctors can adjust the radiation daily to target the tumor more precisely. The goal is to see if this approach improves how long patients live without their cancer growing, while keeping side effects manageable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (dose escalation with reduced margins) plus temozolomide chemotherapy
What this could lead to: If successful, this could offer a more effective, shorter radiation regimen for elderly glioblastoma patients, potentially improving survival without increasing side effects.
What could go wrong: This is a small, early-phase trial with only 55 participants, so results may not apply broadly. The higher radiation dose could still cause brain swelling or other side effects, and survival benefits are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult glioblastoma astrocytoma, IDH-mutant, grade 4 glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME, ADULT GLIOBLASTOMA, IDH-MUTANT

Contacts and locations

Locations

Odette Cancer Centre, Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.